Skip to main content

Table 1 Large intergenic noncoding RNA linc0949 by presence or absence of clinical features of systemic lupus erythematosus a

From: Association of large intergenic noncoding RNA expression with disease activity and organ damage in systemic lupus erythematosus

Clinical features SLE clinical features present SLE clinical features absent P -value
  N Mean ± SEM (range, 10 −3 ) N Mean ± SEM (range, 10 −3 )
Renal 50 2.16 ± 0.152 52 1.47 ± 0.132 0.0014
Rash 33 1.89 ± 0.200 69 1.87 ± 0.199 NS
Arthritis 35 1.79 ± 0.327 67 1.97 ± 0.163 NS
Serositis 21 1.81 ± 0.307 81 1.72 ± 0.364 NS
Mucosal ulcer 19 2.02 ± 0.207 83 1.87 ± 0.187 NS
Hematologic 30 1.84 ± 0.243 72 2.06 ± 0.179 NS
Neurologic 9 1.99 ± 0.084 93 2.05 ± 0.45 NS
Autoantibodies      
  Anti-dsDNA 40 1.91 ± 0.274 62 1.88 ± 0.264 NS
  Anti-Sm 16 2.07 ± 0.202 86 1.78 ± 0.193 NS
  Anti-nucleosome 40 1.91 ± 0.204 62 1.88 ± 0.212 NS
  Anti-SSA/SSB 32 2.03 ± 0.258 70 2.01 ± 0.176 NS
  Anti-RNP 22 1.95 ± 0.253 80 1.96 ± 0.165 NS
Medical therapy      
  Prednisone dose ≥30 mg/day 48 2.08 ± 0.175 54 1.94 ± 0.181 NS
  Immunosuppressantsb 42 2.00 ± 0.141 60 1.54 ± 0.151 0.0365
  1. adsDNA, Double-stranded DNA; NS, Not significant; RNP, Ribonucleoprotein; SEM, Standard error of the mean; SLE, Systemic lupus erythematosus; Sm, Smith; SSA, Sjögren’s syndrome–related antigen A; SSB, Sjögren’s syndrome–related antigen B. bImmunosuppressants included azathioprine, cyclophosphamide, cyclosporine A, FK506 (tacrolimus), leflunomide, mycophenolate mofetil and methotrexate.